TP53 and acute myeloid leukemia: However, one third of pDC-AML cases in our study did not carry RUNX1 mutations, and these RUNX1 wild type cases showed significantly more frequent TP53 mutations, less DNMT3A mutations and conspicuously more frequent CD2 expression on pDCs (68%).